Your search for smoking cessation returned 33 results

The researchers believe that based on their findings, e-cigarette smokers may be at increased risk for bladder cancer.

In a first-ever prospective study evaluating lorcaserin in reducing post-cessation weight gain in overweight and obese smokers, researchers found that lorcaserin combined with varenicline minimized weight gain and increases in waist circumference.

At a joint meeting of the Food and Drug Administration (FDA)’s Psychopharmacologic Drugs Advisory Committee and Drug Safety Risk Management Advisory Committee, a majority vote recommended the removal of the boxed warning regarding serious neuropsychiatric adverse events from the Chantix (varenicline; Pfizer) labeling.

The Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for bupropion extended-release products.

The USPSTF recommended against screening for chronic obstructive pulmonary disease (COPD) in asymptomatic adults.

Researchers from the VA conducted a retrospective cohort study to compare the risk of mental health episodes requiring hospitalization or outpatient clinic visits associated with varenicline vs. nicotine patch use during the time prior to psychiatric boxed warnings.

Nicofi announced the availability of Nicofi sublingual tablets for use as an alternative to smoking.

For current non-daily cigarette smokers, there were statistically significant associations with death from lung cancer, oral cancer, circulatory death, cardiovascular death, cerebrovascular death (stroke), and chronic obstructive pulmonary disease.

The Agency believes decreasing nicotine levels could reduce the risk that future generations will become addicted to cigarettes in addition to allowing current addicts to quit.

Perrigo announced that the Food and Drug Administration (FDA) has approved Abbreviated New Drug Applications (ANDAs) for Nicotine Polacrilex Gum, the generic versions of GlaxoSmithKline’s Nicorette White Ice Mint Gum.